{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:29:30Z","timestamp":1787117370118,"version":"build-2736575974"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"DOI":"10.1007\/s11011-026-01948-z","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:21:19Z","timestamp":1787116879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The potential of vitamins in Huntington\u2019s disease: bridging mechanistic evidence with translational limitations and future strategies"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1493-1629","authenticated-orcid":false,"given":"Vaishnavi Namdeo","family":"Padole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1686-7907","authenticated-orcid":false,"given":"Yogesh A.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"1948_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/BRAIN\/AWAC068","volume":"146","author":"L Abjean","year":"2023","unstructured":"Abjean L, Haim L, Ben, Riquelme-Perez M et al (2023) Reactive astrocytes promote proteostasis in Huntington\u2019s disease through the JAK2-STAT3 pathway. Brain 146:149\u2013166. https:\/\/doi.org\/10.1093\/BRAIN\/AWAC068","journal-title":"Brain"},{"key":"1948_CR2","doi-asserted-by":"publisher","unstructured":"Alangari A (2025) To IV or Not to IV: The science behind intravenous vitamin therapy. Cureus 17. https:\/\/doi.org\/10.7759\/CUREUS.86527","DOI":"10.7759\/CUREUS.86527"},{"key":"1948_CR3","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.3390\/BIOMEDICINES10112866","volume":"10","author":"TH Albekairi","year":"2022","unstructured":"Albekairi TH, Kamra A, Bhardwaj S et al (2022) Beta-Boswellic Acid Reverses 3-Nitropropionic Acid-Induced Molecular, Mitochondrial, and Histopathological Defects in Experimental Rat Model of Huntington\u2019s Disease. Biomedicines 10:2866. https:\/\/doi.org\/10.3390\/BIOMEDICINES10112866","journal-title":"Biomedicines"},{"key":"1948_CR4","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/BRAIN\/AWAE063","volume":"147","author":"SG Aldous","year":"2024","unstructured":"Aldous SG, Smith EJ, Landles C et al (2024) A CAG repeat threshold for therapeutics targeting somatic instability in Huntington\u2019s disease. Brain 147:1784. https:\/\/doi.org\/10.1093\/BRAIN\/AWAE063","journal-title":"Brain"},{"key":"1948_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/BIOMEDICINES12030625","volume":"12","author":"KS Alharbi","year":"2024","unstructured":"Alharbi KS (2024) Europinidin Mitigates 3-NPA-Induced Huntington\u2019s Disease Symptoms in Rats: A Comprehensive Analysis of Oxidative Stress, Mitochondrial Enzyme Complex Activity, Pro-Inflammatory Markers and Neurotransmitter Alterations. Biomedicines 12:625. https:\/\/doi.org\/10.3390\/BIOMEDICINES12030625","journal-title":"Biomedicines"},{"key":"1948_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/S00415-025-13453-X","volume":"272","author":"S Alshimemeri","year":"2025","unstructured":"Alshimemeri S, Shadid AM, Aldraihem O, Alsaber N (2025) Huntington\u2019s disease in MENAT: systematic review and meta-analysis of prevalence, clinical features, and genetics. J Neurol 2025 272:10. https:\/\/doi.org\/10.1007\/S00415-025-13453-X","journal-title":"J Neurol 2025"},{"key":"1948_CR7","doi-asserted-by":"publisher","unstructured":"An Y, Feng L, Zhang X et al (2019) Dietary intakes and biomarker patterns of folate, vitamin B6, and vitamin B12 can be associated with cognitive impairment by hypermethylation of redox-related genes NUDT15 and TXNRD1. Clin Epigenetics 11(1):139. https:\/\/doi.org\/10.1186\/S13148-019-0741-Y","DOI":"10.1186\/S13148-019-0741-Y"},{"key":"1948_CR8","doi-asserted-by":"publisher","unstructured":"Anderson DG, Haagensen M, Ferreira-Correia A et al (2019) Emerging differences between Huntington\u2019s disease-like 2 and Huntington\u2019s disease: A comparison using MRI brain volumetry. Neuroimage Clin 21. https:\/\/doi.org\/10.1016\/j.nicl.2019.101666","DOI":"10.1016\/j.nicl.2019.101666"},{"key":"1948_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/00005072-199704000-00013","volume":"56","author":"T Arzberger","year":"1997","unstructured":"Arzberger T, Krampfl K, Leimgruber S, Weindl A (1997) Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington\u2019s disease - An in situ hybridization study. J Neuropathol Exp Neurol 56:440\u2013454. https:\/\/doi.org\/10.1097\/00005072-199704000-00013","journal-title":"J Neuropathol Exp Neurol"},{"key":"1948_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/mds.28823","volume":"37","author":"HS Bakels","year":"2022","unstructured":"Bakels HS, Roos RAC, van Roon-Mom WMC, de Bot ST (2022) Juvenile\u2010Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review. Mov Disord 37:16\u201324. https:\/\/doi.org\/10.1002\/mds.28823","journal-title":"Mov Disord"},{"key":"1948_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3233\/JHD-240034","volume":"13","author":"HS Bakels","year":"2024","unstructured":"Bakels HS, Feleus S, Rodr\u00edguez-Girondo M et al (2024) Prevalence of Juvenile-Onset and Pediatric Huntington\u2019s Disease and Their Availability and Ability to Participate in Trials: A Dutch Population and Enroll-HD Observational Study. J Huntingtons Dis 13:357\u2013368. https:\/\/doi.org\/10.3233\/JHD-240034","journal-title":"J Huntingtons Dis"},{"key":"1948_CR12","doi-asserted-by":"publisher","first-page":"e213525","DOI":"10.1212\/WNL.0000000000213525","volume":"104","author":"HS Bakels","year":"2025","unstructured":"Bakels HS, Van Der Zwaan KF, Van Zwet E et al (2025) Comparison of the clinical spectrum of juvenile- and adult-onset huntington disease: A national cohort and enroll-HD observational study. Neurology 104:e213525. https:\/\/doi.org\/10.1212\/WNL.0000000000213525 ;REQUESTEDJOURNAL:JOURNAL:WNL;WGROUP:STRING:PUBLICATION","journal-title":"Neurology"},{"key":"1948_CR13","doi-asserted-by":"publisher","first-page":"105574","DOI":"10.1016\/J.NBD.2021.105574","volume":"162","author":"J Barry","year":"2021","unstructured":"Barry J, Bui MTN, Levine MS, Cepeda C (2021) Synaptic pathology in Huntington\u2019s disease: Beyond the corticostriatal pathway. Neurobiol Dis 162:105574. https:\/\/doi.org\/10.1016\/J.NBD.2021.105574","journal-title":"Neurobiol Dis"},{"key":"1948_CR14","doi-asserted-by":"publisher","first-page":"101220","DOI":"10.1016\/J.PLIPRES.2023.101220","volume":"90","author":"P Borel","year":"2023","unstructured":"Borel P, Dangles O, Kopec RE (2023) Fat-soluble vitamin and phytochemical metabolites: Production, gastrointestinal absorption, and health effects. Prog Lipid Res 90:101220. https:\/\/doi.org\/10.1016\/J.PLIPRES.2023.101220","journal-title":"Prog Lipid Res"},{"key":"1948_CR15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0306-9877(81)90046-3","volume":"7","author":"MJW Brennan","year":"1981","unstructured":"Brennan MJW, van der Westhuyzen J, Kramer S, Metz J (1981) Neurotoxicity of folates: implications for vitamin B12 deficiency and Huntington\u2019s chorea. Med Hypotheses 7:919\u2013929. https:\/\/doi.org\/10.1016\/0306-9877(81)90046-3","journal-title":"Med Hypotheses"},{"key":"1948_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.1.6106.153","author":"AJ Caro","year":"1978","unstructured":"Caro AJ, Caro S (1978) Vitamin E in treatment of Huntington\u2019s chorea. Br Med J. https:\/\/doi.org\/10.1136\/BMJ.1.6106.153. 1:153","journal-title":"Br Med J"},{"key":"1948_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/nrn1806","volume":"6","author":"E Cattaneo","year":"2005","unstructured":"Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington\u2019s disease. Nat Rev Neurosci 6:919\u2013930. https:\/\/doi.org\/10.1038\/nrn1806","journal-title":"Nat Rev Neurosci"},{"key":"1948_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/1073858420972662","volume":"28","author":"C Cepeda","year":"2022","unstructured":"Cepeda C, Levine MS (2022) Synaptic Dysfunction in Huntington\u2019s Disease: Lessons from Genetic Animal Models. Neuroscientist 28:20\u201340","journal-title":"Neuroscientist"},{"key":"1948_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/WCO.0000000000001194","volume":"36","author":"P Chen","year":"2023","unstructured":"Chen P, Song XJ (2023) Vitamins in neuropathy: pathophysiological and therapeutic roles. Curr Opin Neurol 36:388\u2013393. https:\/\/doi.org\/10.1097\/WCO.0000000000001194","journal-title":"Curr Opin Neurol"},{"key":"1948_CR19","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/77528","volume":"6","author":"M Chen","year":"2000","unstructured":"Chen M, Ona VO, Li M et al (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797\u2013801. https:\/\/doi.org\/10.1038\/77528","journal-title":"Nat Med"},{"key":"1948_CR21","doi-asserted-by":"publisher","unstructured":"Chennamsetty S, Keerikkadu M, Shetty A, Rathnanand M (2026) Advances in nanoparticle-based vitamin delivery systems for precision nutrition and improved bioavailability. AAPS PharmSciTech 27(3):162-. https:\/\/doi.org\/10.1208\/S12249-026-03410-W","DOI":"10.1208\/S12249-026-03410-W"},{"key":"1948_CR22","unstructured":"ClinicalTrials.gov (2024) Study Details | NCT01574053 | Enroll -HD: A Prospective Registry Study in a Global Huntington\u2019s Disease Cohort | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01574053?utm_source=chatgpt.com. Accessed 19 May 2026"},{"key":"1948_CR23","doi-asserted-by":"publisher","unstructured":"Creus-Muncunill J, Haure-Mirande JV, Mattei D et al (2024) TYROBP\/DAP12 knockout in Huntington\u2019s disease Q175 mice cell-autonomously decreases microglial expression of disease-associated genes and non-cell-autonomously mitigates astrogliosis and motor deterioration. J Neuroinflammation 21. https:\/\/doi.org\/10.1186\/S12974-024-03052-4","DOI":"10.1186\/S12974-024-03052-4"},{"key":"1948_CR24","doi-asserted-by":"publisher","unstructured":"Cuyubamba O, Braga CP, Swift D et al (2025) The combination of neurotropic vitamins B1, B6, and B12 enhances neural cell maturation and connectivity superior to single B vitamins. Cells 14:477. https:\/\/doi.org\/10.3390\/CELLS14070477","DOI":"10.3390\/CELLS14070477"},{"key":"1948_CR25","doi-asserted-by":"publisher","first-page":"611735","DOI":"10.3389\/FCELL.2020.611735\/FULL","volume":"8","author":"M Czeredys","year":"2020","unstructured":"Czeredys M (2020) Dysregulation of Neuronal Calcium Signaling via Store-Operated Channels in Huntington\u2019s Disease. Front Cell Dev Biol 8:611735. https:\/\/doi.org\/10.3389\/FCELL.2020.611735\/FULL","journal-title":"Front Cell Dev Biol"},{"key":"1948_CR129","doi-asserted-by":"publisher","unstructured":"Deshmukh SV, Prabhakar B, Kulkarni YA (2020) Water Soluble Vitamins and their Role in Diabetes and its Complications. Curr Diabetes Rev 16:649\u2013656. https:\/\/doi.org\/10.2174\/1573399815666190916114040","DOI":"10.2174\/1573399815666190916114040"},{"key":"1948_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/J.BIOPHA.2015.11.009","volume":"77","author":"SB Dhadde","year":"2016","unstructured":"Dhadde SB, Nagakannan P, Roopesh M et al (2016) Effect of embelin against 3-nitropropionic acid-induced Huntington\u2019s disease in rats. Biomed Pharmacother 77:52\u201358. https:\/\/doi.org\/10.1016\/J.BIOPHA.2015.11.009","journal-title":"Biomed Pharmacother"},{"key":"1948_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s13311-012-0112-2","volume":"9","author":"ME Ehrlich","year":"2012","unstructured":"Ehrlich ME (2012) Huntington\u2019s Disease and the Striatal Medium Spiny Neuron: Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Disease. Neurotherapeutics 9:270\u2013284. https:\/\/doi.org\/10.1007\/s13311-012-0112-2","journal-title":"Neurotherapeutics"},{"key":"1948_CR131","doi-asserted-by":"publisher","unstructured":"Eide S, Misztal M, Feng ZP (2023) Interleukin-6 as a marker of Huntington\u2019s disease progression: Systematic review and meta-analysis. Brain Behav Immun Health 30. https:\/\/doi.org\/10.1016\/j.bbih.2023.100635","DOI":"10.1016\/j.bbih.2023.100635"},{"key":"1948_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-60556-0","volume":"16","author":"C Estevez-Fraga","year":"2025","unstructured":"Estevez-Fraga C, Sebenius I, Hansen JY et al (2025) Cell-specific mechanisms drive connectivity across the time course of Huntington\u2019s disease. Nat Commun 2025 16:1. https:\/\/doi.org\/10.1038\/s41467-025-60556-0","journal-title":"Nat Commun 2025"},{"key":"1948_CR29","doi-asserted-by":"publisher","unstructured":"Fazio P, Paucar M, Svenningsson P, Varrone A (2018) Novel Imaging Biomarkers for Huntington\u2019s Disease and Other Hereditary Choreas. Curr Neurol Neurosci Rep 1818(12):85. https:\/\/doi.org\/10.1007\/s11910-018-0890-y","DOI":"10.1007\/s11910-018-0890-y"},{"key":"1948_CR30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4103\/1673-5374.230301","volume":"13","author":"L Foucault-Fruchard","year":"2018","unstructured":"Foucault-Fruchard L, Tronel C, Bodard S et al (2018) Alpha-7 nicotinic acetylcholine receptor agonist treatment in a rat model of Huntington\u2019s disease and involvement of heme oxygenase-1. Neural Regen Res 13:737\u2013741. https:\/\/doi.org\/10.4103\/1673-5374.230301","journal-title":"Neural Regen Res"},{"key":"1948_CR132","doi-asserted-by":"publisher","unstructured":"Fung JN, Lee JD, Adam R, et al (2025) Peripheral and central elevation of IL-8 in patients with Huntington\u2019s disease. Mol Immunol 179:84\u201393. https:\/\/doi.org\/10.1016\/j.molimm.2025.02.003","DOI":"10.1016\/j.molimm.2025.02.003"},{"key":"1948_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/S13668-025-00610-X","volume":"14","author":"A Gaba","year":"2025","unstructured":"Gaba A (2025) Nutrition and Huntington\u2019s Disease\u2013 A Review of Current Practice and Theory. Curr Nutr Rep 14:18. https:\/\/doi.org\/10.1007\/S13668-025-00610-X","journal-title":"Curr Nutr Rep"},{"key":"1948_CR32","doi-asserted-by":"publisher","unstructured":"Gatto EM, Rojas NG, Persi G et al (2020) Huntington disease: Advances in the understanding of its mechanisms. Clin Park Relat Disord 3. https:\/\/doi.org\/10.1016\/J.PRDOA.2020.100056","DOI":"10.1016\/J.PRDOA.2020.100056"},{"key":"1948_CR33","doi-asserted-by":"publisher","first-page":"100109","DOI":"10.1016\/J.METOP.2021.100109","volume":"11","author":"MG Grammatikopoulou","year":"2021","unstructured":"Grammatikopoulou MG, Gkiouras K, Dardiotis E et al (2021) Peeking into the future: Transdermal patches for the delivery of micronutrient supplements. Metabol Open 11:100109. https:\/\/doi.org\/10.1016\/J.METOP.2021.100109","journal-title":"Metabol Open"},{"key":"1948_CR34","doi-asserted-by":"publisher","first-page":"751","DOI":"10.17219\/ACEM\/63091","volume":"26","author":"BM Gruber-Bzura","year":"2017","unstructured":"Gruber-Bzura BM, Krzyszto\u0144-Russjan J, Bubko I et al (2017) Role of thiamine in Huntington\u2019s disease pathogenesis: In vitro studies. Adv Clin Exp Med 26:751\u2013760. https:\/\/doi.org\/10.17219\/ACEM\/63091","journal-title":"Adv Clin Exp Med"},{"key":"1948_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ANA.410390317","volume":"39","author":"M Gu","year":"1996","unstructured":"Gu M, Gash MT, Mann VM et al (1996) Mitochondrial defect in Huntington\u2019s disease caudate nucleus. Ann Neurol 39:385\u2013389. https:\/\/doi.org\/10.1002\/ANA.410390317","journal-title":"Ann Neurol"},{"key":"1948_CR36","doi-asserted-by":"publisher","first-page":"711564","DOI":"10.3389\/FNCIR.2021.711564\/XML","volume":"15","author":"C Guo","year":"2021","unstructured":"Guo C, Ma YY (2021) Calcium Permeable-AMPA Receptors and Excitotoxicity in Neurological Disorders. Front Neural Circuits 15:711564. https:\/\/doi.org\/10.3389\/FNCIR.2021.711564\/XML","journal-title":"Front Neural Circuits"},{"key":"1948_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/J.NBD.2010.08.017","volume":"41","author":"T Hathorn","year":"2011","unstructured":"Hathorn T, Snyder-Keller A, Messer A (2011) Nicotinamide improves motor deficits and upregulates PGC-1\u03b1 and BDNF gene expression in a mouse model of Huntington\u2019s disease. Neurobiol Dis 41:43\u201350. https:\/\/doi.org\/10.1016\/J.NBD.2010.08.017","journal-title":"Neurobiol Dis"},{"key":"1948_CR38","doi-asserted-by":"publisher","unstructured":"Heng M, Detloff P, Wang P et al (2008) In vivo evidence for NMDA receptor mediated excitotoxicity in a murine genetic model of Huntington Disease. Nat Precedings 1\u20131. https:\/\/doi.org\/10.1038\/NPRE.2008.1996.1;KWRD","DOI":"10.1038\/NPRE.2008.1996.1;KWRD"},{"key":"1948_CR39","doi-asserted-by":"publisher","unstructured":"Hett K, Dubois A, Leguizamon M et al (2026) Functional and Structural Evidence of Neurofluid Circuit Aberrations in Huntington Disease. Ann Clin Transl Neurol. https:\/\/doi.org\/10.1002\/ACN3.70328. ;CSUBTYPE:STRING:AHEAD","DOI":"10.1002\/ACN3.70328"},{"key":"1948_CR40","doi-asserted-by":"publisher","unstructured":"Hewton KG, Johal AS, Parker SJ (2021) Transporters at the Interface between cytosolic and mitochondrial amino acid metabolism. Metabolites 11:112. https:\/\/doi.org\/10.3390\/METABO11020112","DOI":"10.3390\/METABO11020112"},{"key":"1948_CR41","unstructured":"Huntington\u2019s Disease Society of America Overview of Huntington\u2019s Disease - Huntington\u2019s Disease Society of America. https:\/\/hdsa.org\/what-is-hd\/overview-of-huntingtons-disease\/?utm_source=chatgpt.com. Accessed 19 May 2026"},{"key":"1948_CR43","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/J.BRAINRES.2016.03.034","volume":"1648","author":"Y Jiang","year":"2016","unstructured":"Jiang Y, Chadwick SR, Lajoie P (2016) Endoplasmic reticulum stress: The cause and solution to Huntington\u2019s disease? Brain Res 1648:650\u2013657. https:\/\/doi.org\/10.1016\/J.BRAINRES.2016.03.034","journal-title":"Brain Res"},{"key":"1948_CR42","doi-asserted-by":"publisher","first-page":"13021","DOI":"10.3390\/IJMS241613021","volume":"24","author":"A Jiang","year":"2023","unstructured":"Jiang A, Handley RR, Lehnert K, Snell RG (2023) From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington\u2019s Disease Research. Int J Mol Sci 24:13021. https:\/\/doi.org\/10.3390\/IJMS241613021","journal-title":"Int J Mol Sci"},{"key":"1948_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.freeradbiomed.2013.04.016","volume":"62","author":"A Johri","year":"2013","unstructured":"Johri A, Chandra A, Flint Beal M (2013) PGC-1\u03b1, mitochondrial dysfunction, and Huntington\u2019s disease. Free Radic Biol Med 62:37\u201346. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.04.016","journal-title":"Free Radic Biol Med"},{"key":"1948_CR45","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.4103\/1673-5374.360289","volume":"18","author":"A Jurcau","year":"2022","unstructured":"Jurcau A, Jurcau CM (2022) Mitochondria in Huntington\u2019s disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies. Neural Regen Res 18:1472. https:\/\/doi.org\/10.4103\/1673-5374.360289","journal-title":"Neural Regen Res"},{"key":"1948_CR46","doi-asserted-by":"publisher","unstructured":"Kadowaki H, Nishitoh H (2013) Signaling pathways from the endoplasmic reticulum and their roles in disease. Genes 4:306\u2013333. https:\/\/doi.org\/10.3390\/GENES4030306","DOI":"10.3390\/GENES4030306"},{"key":"1948_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejphar.2010.02.031","volume":"634","author":"H Kalonia","year":"2010","unstructured":"Kalonia H, Kumar P, Kumar A (2010) Targeting oxidative stress attenuates malonic acid induced Huntington like behavioral and mitochondrial alterations in rats. Eur J Pharmacol 634:46\u201352. https:\/\/doi.org\/10.1016\/j.ejphar.2010.02.031","journal-title":"Eur J Pharmacol"},{"key":"1948_CR48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/J.NEUINT.2005.09.002","volume":"48","author":"S Ka\u0161parov\u00e1","year":"2006","unstructured":"Ka\u0161parov\u00e1 S, Sumbalov\u00e1 Z, Bystrick\u00fd P et al (2006) Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington\u2019s disease. Neurochem Int 48:93\u201399. https:\/\/doi.org\/10.1016\/J.NEUINT.2005.09.002","journal-title":"Neurochem Int"},{"key":"1948_CR49","doi-asserted-by":"publisher","first-page":"8363","DOI":"10.3390\/IJMS22168363","volume":"22","author":"A Kim","year":"2021","unstructured":"Kim A, Lalonde K, Truesdell A et al (2021) New Avenues for the Treatment of Huntington\u2019s Disease. Int J Mol Sci 22:8363. https:\/\/doi.org\/10.3390\/IJMS22168363","journal-title":"Int J Mol Sci"},{"key":"1948_CR50","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JHD-160205","volume":"5","author":"A Kumar","year":"2016","unstructured":"Kumar A, Ratan RR (2016) Oxidative Stress and Huntington\u2019s Disease: The Good, The Bad, and The Ugly. J Huntingtons Dis 5:217\u2013237. https:\/\/doi.org\/10.3233\/JHD-160205","journal-title":"J Huntingtons Dis"},{"key":"1948_CR51","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/J.NEUINT.2016.07.008","volume":"99","author":"E Kurtys","year":"2016","unstructured":"Kurtys E, Eisel ULM, Verkuyl JM et al (2016) The combination of vitamins and omega-3 fatty acids has an enhanced anti-inflammatory effect on microglia. Neurochem Int 99:206\u2013214. https:\/\/doi.org\/10.1016\/J.NEUINT.2016.07.008","journal-title":"Neurochem Int"},{"key":"1948_CR52","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/JAMANEUROL.2019.2368","volume":"76","author":"DR Langbehn","year":"2019","unstructured":"Langbehn DR, Stout JC, Gregory S et al (2019) Association of CAG Repeats with Long-term Progression in Huntington Disease. JAMA Neurol 76:1375\u20131385. https:\/\/doi.org\/10.1001\/JAMANEUROL.2019.2368","journal-title":"JAMA Neurol"},{"key":"1948_CR53","doi-asserted-by":"publisher","first-page":"105076","DOI":"10.1016\/J.NBD.2020.105076","volume":"145","author":"M Lebouc","year":"2020","unstructured":"Lebouc M, Richard Q, Garret M, Baufreton J (2020) Striatal circuit development and its alterations in Huntington\u2019s disease. Neurobiol Dis 145:105076. https:\/\/doi.org\/10.1016\/J.NBD.2020.105076","journal-title":"Neurobiol Dis"},{"key":"1948_CR54","doi-asserted-by":"publisher","unstructured":"Lim RG, Al-Dalahmah O, Wu J et al (2022) Huntington disease oligodendrocyte maturation deficits revealed by single-nucleus RNA-seq are rescued by thiamine-biotin supplementation. Nat Commun 13. https:\/\/doi.org\/10.1038\/S41467-022-35388-X","DOI":"10.1038\/S41467-022-35388-X"},{"key":"1948_CR55","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/acn3.51142","volume":"7","author":"J Lo","year":"2020","unstructured":"Lo J, Reyes A, Pulverenti TS et al (2020) Dual tasking impairments are associated with striatal pathology in Huntington\u2019s disease. Ann Clin Transl Neurol 7:1608\u20131619. https:\/\/doi.org\/10.1002\/acn3.51142","journal-title":"Ann Clin Transl Neurol"},{"key":"1948_CR56","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/J.NBD.2012.02.012","volume":"46","author":"JD Long","year":"2012","unstructured":"Long JD, Matson WR, Juhl AR et al (2012) 8OHdG as a marker for Huntington disease progression. Neurobiol Dis 46:625\u2013634. https:\/\/doi.org\/10.1016\/J.NBD.2012.02.012","journal-title":"Neurobiol Dis"},{"key":"1948_CR57","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.nut.2004.04.001","volume":"20","author":"HC Lukaski","year":"2004","unstructured":"Lukaski HC (2004) Vitamin and mineral status: Effects on physical performance. Nutrition 20:632\u2013644. https:\/\/doi.org\/10.1016\/j.nut.2004.04.001","journal-title":"Nutrition"},{"key":"1948_CR58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/PNP.664","volume":"24","author":"N Majothi","year":"2020","unstructured":"Majothi N, Lee HY, Nagarajan P, Vutla R (2020) Treatment of psychosis in Huntington\u2019s disease with clozapine. Prog Neurol Psychiatry 24:14\u201316. https:\/\/doi.org\/10.1002\/PNP.664","journal-title":"Prog Neurol Psychiatry"},{"key":"1948_CR60","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neuroscience.2022.03.039","volume":"492","author":"SKV Manjari","year":"2022","unstructured":"Manjari SKV, Maity S, Poornima R et al (2022) Restorative Action of Vitamin D3 on Motor Dysfunction Through Enhancement of Neurotrophins and Antioxidant Expression in the Striatum. Neuroscience 492:67\u201381. https:\/\/doi.org\/10.1016\/j.neuroscience.2022.03.039","journal-title":"Neuroscience"},{"key":"1948_CR59","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ibneur.2023.07.001","volume":"15","author":"SKV Manjari","year":"2023","unstructured":"Manjari SKV, Abraham SM, Poornima R et al (2023) Unprecedented effect of vitamin D3 on T-cell receptor beta subunit and alpha7 nicotinic acetylcholine receptor expression in a 3-nitropropionic acid-induced mouse model of Huntington\u2019s disease. IBRO Neurosci Rep 15:116\u2013125. https:\/\/doi.org\/10.1016\/j.ibneur.2023.07.001","journal-title":"IBRO Neurosci Rep"},{"key":"1948_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-64936-4","volume":"16","author":"EW Mathews","year":"2025","unstructured":"Mathews EW, Coffey SR, G\u00e4rtner A et al (2025) Suppression of Huntington\u2019s Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding. Nat Commun 2025 16:1. https:\/\/doi.org\/10.1038\/s41467-025-64936-4","journal-title":"Nat Commun 2025"},{"key":"1948_CR62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi SJ (2018) Huntington\u2019s disease: a clinical review. Eur J Neurol 25:24\u201334. https:\/\/doi.org\/10.1111\/ene.13413","journal-title":"Eur J Neurol"},{"key":"1948_CR63","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/jnnp.35.4.510","volume":"35","author":"WR McLeod","year":"1972","unstructured":"McLeod WR, Horne DJ (1972) Huntington\u2019s chorea and tryptophan. J Neurol Neurosurg Psychiatry 35:510\u2013513. https:\/\/doi.org\/10.1136\/jnnp.35.4.510","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1948_CR64","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/mds.29228","volume":"37","author":"A Medina","year":"2022","unstructured":"Medina A, Mahjoub Y, Shaver L, Pringsheim T (2022) Prevalence and Incidence of Huntington\u2019s Disease: An Updated Systematic Review and Meta-Analysis. Mov Disord 37:2327\u20132335. https:\/\/doi.org\/10.1002\/mds.29228","journal-title":"Mov Disord"},{"key":"1948_CR65","doi-asserted-by":"publisher","first-page":"e71238","DOI":"10.1002\/BRB3","volume":"16","author":"S Migliore","year":"2026","unstructured":"Migliore S, Marcaccio M, Di Pompeo I et al (2026) Executive Impairment in Huntington\u2019s Disease: Insights From a Systematic Review of the Literature. Brain Behav 16:e71238. https:\/\/doi.org\/10.1002\/BRB371238;CTYPE:STRING:JOURNAL","journal-title":"Brain Behav"},{"key":"1948_CR66","doi-asserted-by":"publisher","first-page":"e647","DOI":"10.1371\/JOURNAL.PONE.0000647","volume":"2","author":"F Mochel","year":"2007","unstructured":"Mochel F, Charles P, Seguin F et al (2007) Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease Progression. PLoS ONE 2:e647. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0000647","journal-title":"PLoS ONE"},{"key":"1948_CR67","doi-asserted-by":"publisher","first-page":"9961","DOI":"10.2147\/IJN.S276355","volume":"15","author":"AS Mohd Zaffarin","year":"2020","unstructured":"Mohd Zaffarin AS, Ng SF, Ng MH et al (2020) Pharmacology and pharmacokinetics of Vitamin E: Nanoformulations to enhance bioavailability. Int J Nanomed 15:9961\u20139974. https:\/\/doi.org\/10.2147\/IJN.S276355","journal-title":"Int J Nanomed"},{"key":"1948_CR68","doi-asserted-by":"publisher","first-page":"176","DOI":"10.21307\/ANE-2017-017","volume":"76","author":"MF Moln\u00e1r","year":"2016","unstructured":"Moln\u00e1r MF, T\u00f6r\u00f6k R, Szal\u00e1rdy L et al (2016) High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of huntington\u2019s disease transgenic mice. Acta Neurobiol Exp (Wars) 76:176\u2013181. https:\/\/doi.org\/10.21307\/ANE-2017-017","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"1948_CR70","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1007\/S12035-016-0048-3","volume":"54","author":"L Naia","year":"2017","unstructured":"Naia L, Rosenstock TR, Oliveira AM et al (2017) Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington\u2019s Disease Models. Mol Neurobiol 54:5385\u20135399. https:\/\/doi.org\/10.1007\/S12035-016-0048-3","journal-title":"Mol Neurobiol"},{"key":"1948_CR71","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/BRAIN\/AWAB367","volume":"145","author":"A Nair","year":"2022","unstructured":"Nair A, Razi A, Gregory S et al (2022) Imbalanced basal ganglia connectivity is associated with motor deficits and apathy in Huntington\u2019s disease. Brain 145:991\u20131000. https:\/\/doi.org\/10.1093\/BRAIN\/AWAB367","journal-title":"Brain"},{"key":"1948_CR72","doi-asserted-by":"publisher","first-page":"e0146480","DOI":"10.1371\/JOURNAL.PONE.0146480","volume":"11","author":"R Nambron","year":"2016","unstructured":"Nambron R, Silajd\u017ei\u0107 E, Kalliolia E et al (2016) A Metabolic Study of Huntington\u2019s Disease. PLoS ONE 11:e0146480. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0146480","journal-title":"PLoS ONE"},{"key":"1948_CR73","doi-asserted-by":"publisher","first-page":"115639","DOI":"10.1016\/J.EXPNEUROL.2026.115639","volume":"398","author":"E Paldino","year":"2026","unstructured":"Paldino E, Montalesi E, Fiocchetti M et al (2026) Daily intranasal resveratrol-conjugated gold nanoparticles administration promotes neuroprotection and improves neurological outcome in the R6\/2 mouse model of Huntington\u2019s disease. Exp Neurol 398:115639. https:\/\/doi.org\/10.1016\/J.EXPNEUROL.2026.115639","journal-title":"Exp Neurol"},{"key":"1948_CR74","doi-asserted-by":"publisher","unstructured":"Paleacu D, Diana P (2022) Neuropsychiatric disease and treatment tetrabenazine in the treatment of Huntington\u2019s disease 545 E X P E RT O P I N I O N Tetrabenazine in the treatment of Huntington\u2019s disease. https:\/\/doi.org\/10.2147\/NDT.S12160202","DOI":"10.2147\/NDT.S12160202"},{"key":"1948_CR75","doi-asserted-by":"publisher","unstructured":"Patassini S, Begley P, Xu J et al (2019) Cerebral vitamin B5 (D-Pantothenic Acid) deficiency as a potential cause of metabolic perturbation and neurodegeneration in Huntington\u2019s disease. Metabolites 9. https:\/\/doi.org\/10.3390\/METABO9060113","DOI":"10.3390\/METABO9060113"},{"key":"1948_CR77","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.4103\/NRR.NRR-D-24-00630","volume":"20","author":"Y Peng","year":"2024","unstructured":"Peng Y, Zhou L, Jin Y et al (2024) Calcium bridges built by mitochondria-associated endoplasmic reticulum membranes: potential targets for neural repair in neurological diseases. Neural Regen Res 20:3349. https:\/\/doi.org\/10.4103\/NRR.NRR-D-24-00630","journal-title":"Neural Regen Res"},{"key":"1948_CR76","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.21037\/TP-2025-507","volume":"14","author":"L Peng","year":"2025","unstructured":"Peng L, Zhao J, Duan C et al (2025) Effects of vitamin A and vitamin D3 supplementation on child growth and development in low- and middle-income countries: a systematic review and meta-analysis. Transl Pediatr 14:3281\u20133292. https:\/\/doi.org\/10.21037\/TP-2025-507","journal-title":"Transl Pediatr"},{"key":"1948_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12868-018-0474-4\/FIGURES\/6","volume":"19","author":"AV Peraza","year":"2018","unstructured":"Peraza AV, Guzm\u00e1n DC, Brizuela NO et al (2018) Riboflavin and pyridoxine restore dopamine levels and reduce oxidative stress in brain of rats. BMC Neurosci 19:1\u20138. https:\/\/doi.org\/10.1186\/S12868-018-0474-4\/FIGURES\/6","journal-title":"BMC Neurosci"},{"key":"1948_CR79","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1176\/AJP.152.12.1771","volume":"152","author":"CE Peyser","year":"1995","unstructured":"Peyser CE, Folstein M, Chase GA et al (1995) Trial of d-\u03b1-tocopherol in Huntington\u2019s disease. Am J Psychiatry 152:1771\u20131775. https:\/\/doi.org\/10.1176\/AJP.152.12.1771","journal-title":"Am J Psychiatry"},{"key":"1948_CR80","doi-asserted-by":"publisher","unstructured":"Pic\u00f3 S, Parras A, Santos-Galindo M et al (2021) CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington\u2019s disease. Sci Transl Med 13. https:\/\/doi.org\/10.1126\/SCITRANSLMED.ABE7104","DOI":"10.1126\/SCITRANSLMED.ABE7104"},{"key":"1948_CR82","doi-asserted-by":"publisher","unstructured":"Pradhan SS, Rao KR, Manjunath M et al (2023) Vitamin B6, B12 and folate modulate deregulated pathways and protein aggregation in yeast model of Huntington disease. 3 Biotech 13. https:\/\/doi.org\/10.1007\/S13205-023-03525-Y","DOI":"10.1007\/S13205-023-03525-Y"},{"key":"1948_CR81","doi-asserted-by":"publisher","first-page":"7974","DOI":"10.1021\/ACSANM.5C00240","volume":"8","author":"N Pradhan","year":"2025","unstructured":"Pradhan N, Shaw S, Jana NR (2025) Nanoascorbate Promotes Clearance of Mutant Huntingtin Aggregates via Restoration of Blocked Autophagy. ACS Appl Nano Mater 8:7974\u20137988. https:\/\/doi.org\/10.1021\/ACSANM.5C00240","journal-title":"ACS Appl Nano Mater"},{"key":"1948_CR83","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1113\/EPH8602216","volume":"86","author":"BK Puri","year":"2001","unstructured":"Puri BK (2001) Impaired phospholipid-related signal transduction in advanced Huntington\u2019s disease. Exp Physiol 86:683\u2013685. https:\/\/doi.org\/10.1113\/EPH8602216","journal-title":"Exp Physiol"},{"key":"1948_CR84","doi-asserted-by":"publisher","first-page":"1023907","DOI":"10.3389\/FPUBH.2023.1023907","volume":"11","author":"S Puri","year":"2023","unstructured":"Puri S, Shaheen M, Grover B (2023) Nutrition and cognitive health: A life course approach. Front Public Health 11:1023907. https:\/\/doi.org\/10.3389\/FPUBH.2023.1023907","journal-title":"Front Public Health"},{"key":"1948_CR85","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2217\/nmt.13.18","volume":"3","author":"OW Quarrell","year":"2013","unstructured":"Quarrell OW, Nance MA, Nopoulos P et al (2013) Managing Juvenile Huntington\u2019s Disease. Neurodegener Dis Manag 3:267\u2013276. https:\/\/doi.org\/10.2217\/nmt.13.18","journal-title":"Neurodegener Dis Manag"},{"key":"1948_CR86","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/ILAR.48.4.356","volume":"48","author":"S Ramaswamy","year":"2007","unstructured":"Ramaswamy S, McBride JL, Kordower JH (2007) Animal Models of Huntington\u2019s Disease. ILAR J 48:356\u2013373. https:\/\/doi.org\/10.1093\/ILAR.48.4.356","journal-title":"ILAR J"},{"key":"1948_CR87","doi-asserted-by":"publisher","first-page":"1646750","DOI":"10.3389\/FNUT.2025.1646750\/FULL","volume":"12","author":"JD Richards","year":"2025","unstructured":"Richards JD, Cori H, Rahn M et al (2025) Micronutrient bioavailability: concepts, influencing factors, and strategies for improvement. Front Nutr 12:1646750. https:\/\/doi.org\/10.3389\/FNUT.2025.1646750\/FULL","journal-title":"Front Nutr"},{"key":"1948_CR88","doi-asserted-by":"publisher","first-page":"8653132","DOI":"10.1155\/2016\/8653132","volume":"2016","author":"NP Rocha","year":"2016","unstructured":"Rocha NP, Ribeiro FM, Furr-Stimming E, Teixeira AL (2016) Neuroimmunology of Huntington\u2019s Disease: Revisiting Evidence from Human Studies. Mediators Inflamm 2016:8653132. https:\/\/doi.org\/10.1155\/2016\/8653132","journal-title":"Mediators Inflamm"},{"key":"1948_CR90","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/S00018-023-05015-Z","volume":"80","author":"E Rodr\u00edguez-Urgell\u00e9s","year":"2023","unstructured":"Rodr\u00edguez-Urgell\u00e9s E, Casas-Torremocha D, Sancho-Balsells A et al (2023) Thalamic Foxp2 regulates output connectivity and sensory-motor impairments in a model of Huntington\u2019s Disease. Cell Mol Life Sci 80:367. https:\/\/doi.org\/10.1007\/S00018-023-05015-Z","journal-title":"Cell Mol Life Sci"},{"key":"1948_CR89","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.ABC2888","author":"FB Rodrigues","year":"2020","unstructured":"Rodrigues FB, Byrne LM, Tortelli R et al (2020) Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington\u2019s disease. Sci Transl Med. https:\/\/doi.org\/10.1126\/SCITRANSLMED.ABC2888;JOURNAL:JOURNAL:STM;PAGE:STRING:ARTICLE\/CHAPTER 12:","journal-title":"Sci Transl Med"},{"key":"1948_CR91","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/NRNEUROL.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10:204\u2013216. https:\/\/doi.org\/10.1038\/NRNEUROL.2014.24","journal-title":"Nat Rev Neurol"},{"key":"1948_CR92","doi-asserted-by":"publisher","unstructured":"Roussakis AA, Gennaro M, Gordon MF et al (2023) A PET-CT study on neuroinflammation in Huntington\u2019s disease patients participating in a randomized trial with laquinimod. Brain Commun 5. https:\/\/doi.org\/10.1093\/BRAINCOMMS\/FCAD084","DOI":"10.1093\/BRAINCOMMS\/FCAD084"},{"key":"1948_CR93","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/J.1750-3639.2012.00629.X","volume":"23","author":"U R\u00fcb","year":"2012","unstructured":"R\u00fcb U, Hoche F, Brunt ER et al (2012) Degeneration of the Cerebellum in Huntington\u2019s Disease (HD): Possible Relevance for the Clinical Picture and Potential Gateway to Pathological Mechanisms of the Disease Process. Brain Pathol 23:165. https:\/\/doi.org\/10.1111\/J.1750-3639.2012.00629.X","journal-title":"Brain Pathol"},{"key":"1948_CR94","doi-asserted-by":"publisher","unstructured":"Sarath AM, Thapliyal D, Borthakur S et al (2026) Molecular mechanisms, clinical phenotypes, and advances in Huntington\u2019s disease therapeutics. Discov Neurosci 21(1):51. https:\/\/doi.org\/10.1186\/S13064-026-00282-5","DOI":"10.1186\/S13064-026-00282-5"},{"key":"1948_CR95","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/S10787-020-00787-3\/METRICS","volume":"29","author":"P Saroj","year":"2021","unstructured":"Saroj P, Bansal Y, Singh R et al (2021) Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington\u2019s disease through inhibition of NF-\u03baB mediated neuroinflammatory markers and activation of cAMP\/CREB\/BDNF signaling pathway. Inflammopharmacology 29:499\u2013511. https:\/\/doi.org\/10.1007\/S10787-020-00787-3\/METRICS","journal-title":"Inflammopharmacology"},{"key":"1948_CR96","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1586\/14737175.2015.1025383","volume":"15","author":"LC Schwab","year":"2015","unstructured":"Schwab LC, Garas SN, Drouin-Ouellet J et al (2015) Dopamine and Huntington\u2019s disease. Expert Rev Neurother 15:445\u2013458. https:\/\/doi.org\/10.1586\/14737175.2015.1025383","journal-title":"Expert Rev Neurother"},{"key":"1948_CR97","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jsbmb.2017.06.006","volume":"177","author":"R Scragg","year":"2018","unstructured":"Scragg R (2018) Limitations of vitamin D supplementation trials: Why observational studies will continue to help determine the role of vitamin D in health. J Steroid Biochem Mol Biol 177:6\u20139. https:\/\/doi.org\/10.1016\/j.jsbmb.2017.06.006","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1948_CR98","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/J.DRUDIS.2014.02.006","volume":"19","author":"MD Sepers","year":"2014","unstructured":"Sepers MD, Raymond LA (2014) Mechanisms of synaptic dysfunction and excitotoxicity in Huntington\u2019s disease. Drug Discov Today 19:990\u2013996. https:\/\/doi.org\/10.1016\/J.DRUDIS.2014.02.006","journal-title":"Drug Discov Today"},{"key":"1948_CR99","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00210-021-02106-1","volume":"394","author":"P Sharma","year":"2021","unstructured":"Sharma P, Kumar M, Bansal N (2021) Ellagic acid prevents 3-nitropropionic acid induced symptoms of Huntington\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol 394:1917\u20131928. https:\/\/doi.org\/10.1007\/s00210-021-02106-1","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1948_CR100","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-3-032-14445-4_5\/SAVE-RESEARCH","volume":"36","author":"D Sheth","year":"2026","unstructured":"Sheth D, Awate SA, Buttar HS, Kaur G (2026) The Neuroprotective Role of Micronutrients: A Systematic Review of Preclinical and Clinical Studies on Antioxidant Vitamins, Essential Minerals, and Trace Elements in Managing Neurodegenerative Diseases. Adv Biochem Health Disease 36:85\u2013113. https:\/\/doi.org\/10.1007\/978-3-032-14445-4_5\/SAVE-RESEARCH","journal-title":"Adv Biochem Health Disease"},{"key":"1948_CR130","doi-asserted-by":"publisher","unstructured":"Silvestroni A, Faull RLM, Strand AD, M\u00f6llera T (2009) Distinct neuroinflammatory profile in post-mortem human Huntington\u2019s disease. Neuroreport 20:1098\u20131103. https:\/\/doi.org\/10.1097\/WNR.0B013E32832E34EE","DOI":"10.1097\/WNR.0B013E32832E34EE"},{"key":"1948_CR101","doi-asserted-by":"publisher","first-page":"105047","DOI":"10.1016\/J.JFF.2022.105047","volume":"92","author":"P Singh","year":"2022","unstructured":"Singh P, Mishra G, Molla M et al (2022) Dietary and nutraceutical-based therapeutic approaches to combat the pathogenesis of Huntington\u2019s disease. J Funct Foods 92:105047. https:\/\/doi.org\/10.1016\/J.JFF.2022.105047","journal-title":"J Funct Foods"},{"key":"1948_CR102","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/J.ARR.2018.11.006","volume":"49","author":"TR Soares","year":"2019","unstructured":"Soares TR, Reis SD, Pinho BR et al (2019) Targeting the proteostasis network in Huntington\u2019s disease. Ageing Res Rev 49:92. https:\/\/doi.org\/10.1016\/J.ARR.2018.11.006","journal-title":"Ageing Res Rev"},{"key":"1948_CR103","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/J.1471-4159.2009.06326.X","volume":"111","author":"R Spector","year":"2009","unstructured":"Spector R (2009) Nutrient transport systems in brain: 40 years of progress. J Neurochem 111:315\u2013320. https:\/\/doi.org\/10.1111\/J.1471-4159.2009.06326.X","journal-title":"J Neurochem"},{"key":"1948_CR104","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/J.1471-4159.2007.04773.X","volume":"103","author":"R Spector","year":"2007","unstructured":"Spector R, Johanson CE (2007) REVIEW: Vitamin transport and homeostasis in mammalian brain: focus on Vitamins B and E. J Neurochem 103:425\u2013438. https:\/\/doi.org\/10.1111\/J.1471-4159.2007.04773.X","journal-title":"J Neurochem"},{"key":"1948_CR105","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/FSN3.3787","volume":"12","author":"VV Sugandhi","year":"2023","unstructured":"Sugandhi VV, Pangeni R, Vora LK et al (2023) Pharmacokinetics of vitamin dosage forms: A complete overview. Food Sci Nutr 12:48. https:\/\/doi.org\/10.1002\/FSN3.3787","journal-title":"Food Sci Nutr"},{"key":"1948_CR106","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/J.JNS.2011.12.014","volume":"315","author":"I Tasset","year":"2012","unstructured":"Tasset I, S\u00e1nchez-L\u00f3pez F, Ag\u00fcera E et al (2012) NGF and nitrosative stress in patients with Huntington\u2019s disease. J Neurol Sci 315:133\u2013136. https:\/\/doi.org\/10.1016\/J.JNS.2011.12.014","journal-title":"J Neurol Sci"},{"key":"1948_CR107","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1100\/tsw.2010.164","volume":"10","author":"MT Tebano","year":"2010","unstructured":"Tebano MT, Martire A, Chiodi V et al (2010) Role of adenosine A2A receptors in modulating synaptic functions and brain levels of BDNF: A possible key mechanism in the pathophysiology of Huntington\u2019s disease. ScientificWorldJournal 10:1768\u20131782","journal-title":"ScientificWorldJournal"},{"key":"1948_CR108","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1146\/ANNUREV-NUTR-082018-124235","volume":"39","author":"KA Tiani","year":"2019","unstructured":"Tiani KA, Stover PJ, Field MS (2019) The Role of Brain Barriers in Maintaining Brain Vitamin Levels. Annu Rev Nutr 39:147. https:\/\/doi.org\/10.1146\/ANNUREV-NUTR-082018-124235","journal-title":"Annu Rev Nutr"},{"key":"1948_CR109","doi-asserted-by":"publisher","unstructured":"Tong H, Yang T, Xu S et al (2024) Huntington\u2019s disease: Complex pathogenesis and therapeutic strategies. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/IJMS25073845","DOI":"10.3390\/IJMS25073845"},{"key":"1948_CR110","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/molecules15020878","volume":"15","author":"I T\u00fanez","year":"2010","unstructured":"T\u00fanez I, Tasset I, P\u00e9rez-De La Cruz V, Santamar\u00eda A (2010) 3-Nitropropionic Acid as a Tool to Study the Mechanisms Involved in Huntington\u2019s Disease: Past, Present and Future. Molecules 15:878\u2013916. https:\/\/doi.org\/10.3390\/molecules15020878","journal-title":"Molecules"},{"key":"1948_CR111","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1002\/MDS.21540","volume":"22","author":"C Turner","year":"2007","unstructured":"Turner C, Cooper JM, Schapira AHV (2007) Clinical correlates of mitochondrial function in Huntington\u2019s disease muscle. Mov Disord 22:1715\u20131721. https:\/\/doi.org\/10.1002\/MDS.21540","journal-title":"Mov Disord"},{"issue":"4","key":"1948_CR113","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/S43440-024-00619-Z","volume":"76","author":"S Upadhayay","year":"2024","unstructured":"Upadhayay S, Kumar P (2024) Mitochondrial targeted antioxidants as potential therapy for huntington\u2019s disease. Pharmacol Rep 2024 76(4):693\u2013713. https:\/\/doi.org\/10.1007\/S43440-024-00619-Z","journal-title":"Pharmacol Rep 2024"},{"issue":"6 48","key":"1948_CR114","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/S11064-023-03868-1","volume":"48","author":"S Upadhayay","year":"2023","unstructured":"Upadhayay S, Yedke NG, Rahi V et al (2023b) An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington\u2019s Disease Model and Its Relevance to Drug Discovery and Development. Neurochemical Res 2023 48(6 48):1631\u20131647. https:\/\/doi.org\/10.1007\/S11064-023-03868-1","journal-title":"Neurochemical Res 2023"},{"key":"1948_CR112","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17460441.2023.2201493","volume":"18","author":"S Upadhayay","year":"2023","unstructured":"Upadhayay S, Jamwal S, Kumar P (2023a) Animal models of Huntington\u2019s disease and their applicability to novel drug discovery and development. Expert Opin Drug Discov 18:527\u2013538. https:\/\/doi.org\/10.1080\/17460441.2023.2201493","journal-title":"Expert Opin Drug Discov"},{"key":"1948_CR115","doi-asserted-by":"publisher","DOI":"10.4103\/NRR.NRR-D-25-00089","author":"Z Wang","year":"2025","unstructured":"Wang Z, Sun Y, Luo M et al (2025) Prostaglandins: Key players in immunomodulation of the nervous system. Neural Regen Res. https:\/\/doi.org\/10.4103\/NRR.NRR-D-25-00089","journal-title":"Neural Regen Res"},{"key":"1948_CR116","doi-asserted-by":"publisher","first-page":"e084097","DOI":"10.1002\/ALZ.084097","volume":"20","author":"G Wheildon","year":"2024","unstructured":"Wheildon G, Weymouth L, Smith A et al (2024) Prostaglandin D2 synthase is differentially methylated specifically in Huntington\u2019s Disease. Alzheimer\u2019s Dement 20:e084097. https:\/\/doi.org\/10.1002\/ALZ.084097","journal-title":"Alzheimer\u2019s Dement"},{"key":"1948_CR117","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1111\/ENE.15918","volume":"30","author":"P Wibawa","year":"2023","unstructured":"Wibawa P, Walterfang M, Malpas CB et al (2023) Selective perforant-pathway atrophy in Huntington disease: MRI analysis of hippocampal subfields. Eur J Neurol 30:2650. https:\/\/doi.org\/10.1111\/ENE.15918","journal-title":"Eur J Neurol"},{"key":"1948_CR118","doi-asserted-by":"publisher","unstructured":"Wong WF, Ang KP, Sethi G, Looi CY (2023) Recent advancement of medical patch for transdermal drug delivery. Med (Kaunas) 59. https:\/\/doi.org\/10.3390\/MEDICINA59040778","DOI":"10.3390\/MEDICINA59040778"},{"key":"1948_CR119","doi-asserted-by":"publisher","first-page":"e70182","DOI":"10.1096\/FJ.202401465","volume":"38","author":"M Wozna-Wysocka","year":"2024","unstructured":"Wozna-Wysocka M, Jazurek-Ciesiolka M, Przybyl L et al (2024) Insights into RNA-mediated pathology in new mouse models of Huntington\u2019s disease. FASEB J 38:e70182. https:\/\/doi.org\/10.1096\/FJ.202401465R;WEBSITE:WEBSITE:FASEB;PAGE:STRING:ARTICLE\/CHAPTER","journal-title":"FASEB J"},{"key":"1948_CR120","doi-asserted-by":"publisher","first-page":"107459","DOI":"10.1016\/J.NBD.2026.107459","volume":"226","author":"CW Wu","year":"2026","unstructured":"Wu CW, Chang CP, Hwang DW et al (2026) ROS-HIF1\u03b1-driven glycolytic reprogramming sustains ATP production in Huntington\u2019s disease. Neurobiol Dis 226:107459. https:\/\/doi.org\/10.1016\/J.NBD.2026.107459","journal-title":"Neurobiol Dis"},{"key":"1948_CR122","doi-asserted-by":"publisher","first-page":"1175598","DOI":"10.3389\/FNAGI.2023.1175598\/TEXT","volume":"15","author":"J Yang","year":"2023","unstructured":"Yang J, Zhang C (2023) Targeting the autophagy-lysosomal pathway in Huntington disease: a pharmacological perspective. Front Aging Neurosci 15:1175598. https:\/\/doi.org\/10.3389\/FNAGI.2023.1175598\/TEXT","journal-title":"Front Aging Neurosci"},{"key":"1948_CR121","doi-asserted-by":"publisher","unstructured":"Yang HM, Yang S, Huang SS et al (2017) Microglial activation in the pathogenesis of Huntington\u2019s Disease. Front Aging Neurosci 9. https:\/\/doi.org\/10.3389\/FNAGI.2017.00193","DOI":"10.3389\/FNAGI.2017.00193"},{"key":"1948_CR128","unstructured":"Yero T, Rey JA (2008) Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington\u2019s Disease\u2013Related Chorea. Pharm Ther 33:690"},{"key":"1948_CR123","doi-asserted-by":"publisher","unstructured":"Yetley EA (2007) Multivitamin and multimineral dietary supplements: definitions, characterization, bioavailability, and drug interactions. Am J Clin Nutr 85:269S\u2013276S. https:\/\/doi.org\/10.1093\/AJCN\/85.1.269S","DOI":"10.1093\/AJCN\/85.1.269S"},{"key":"1948_CR124","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/J.CCCN.2003.11.003","volume":"340","author":"SMKR Zaidi","year":"2004","unstructured":"Zaidi SMKR, Banu N (2004) Antioxidant potential of vitamins A, E and C in modulating oxidative stress in rat brain. Clin Chim Acta 340:229\u2013233. https:\/\/doi.org\/10.1016\/J.CCCN.2003.11.003","journal-title":"Clin Chim Acta"},{"key":"1948_CR125","doi-asserted-by":"publisher","first-page":"8574","DOI":"10.3390\/IJMS24108574","volume":"24","author":"D Zajac","year":"2023","unstructured":"Zajac D, Wojciechowski P (2023) The Role of Vitamins in the Pathogenesis of Asthma. Int J Mol Sci 24:8574. https:\/\/doi.org\/10.3390\/IJMS24108574","journal-title":"Int J Mol Sci"},{"key":"1948_CR126","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.mcn.2003.11.014","volume":"25","author":"MM Zeron","year":"2004","unstructured":"Zeron MM, Fernandes HB, Krebs C et al (2004) Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington\u2019s disease. Mol Cell Neurosci 25:469\u2013479. https:\/\/doi.org\/10.1016\/j.mcn.2003.11.014","journal-title":"Mol Cell Neurosci"},{"key":"1948_CR127","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/S00394-023-03124-W","volume":"62","author":"A Zittermann","year":"2023","unstructured":"Zittermann A, Trummer C, Theiler-Schwetz V, Pilz S (2023) Long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events: a systematic review and meta-analysis of randomized controlled trials. Eur J Nutr 62:1833\u20131844. https:\/\/doi.org\/10.1007\/S00394-023-03124-W","journal-title":"Eur J Nutr"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01948-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-026-01948-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01948-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:21:22Z","timestamp":1787116882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-026-01948-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1948"],"URL":"https:\/\/doi.org\/10.1007\/s11011-026-01948-z","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"187"}}